Acrivon Therapeutics Files 8-K
Ticker: ACRV · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1781174
| Field | Detail |
|---|---|
| Company | Acrivon Therapeutics, Inc. (ACRV) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
Related Tickers: ACRV
TL;DR
ACRV filed an 8-K, standard disclosures, nothing major to report.
AI Summary
Acrivon Therapeutics, Inc. filed an 8-K on April 7, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine update for investors, indicating that Acrivon Therapeutics has made required disclosures and submitted financial statements.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no indication of significant new risks or material adverse events.
Key Players & Entities
- Acrivon Therapeutics, Inc. (company) — Registrant
- April 07, 2025 (date) — Date of earliest event reported
- 001-41551 (other) — Commission File Number
- 82-5125532 (other) — IRS Employer Identification No.
- 480 Arsenal Way Suite 100 (address) — Principal Executive Offices
- Watertown, Massachusetts (location) — Principal Executive Offices Location
- 02472 (zip_code) — Principal Executive Offices Zip Code
- (617) 207-8979 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Acrivon Therapeutics?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and to submit Financial Statements and Exhibits as of April 7, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is April 07, 2025.
What is Acrivon Therapeutics, Inc.'s Commission File Number?
Acrivon Therapeutics, Inc.'s Commission File Number is 001-41551.
Where are Acrivon Therapeutics, Inc.'s principal executive offices located?
Acrivon Therapeutics, Inc.'s principal executive offices are located at 480 Arsenal Way Suite 100, Watertown, Massachusetts, 02472.
Does this filing indicate any specific new material events or financial results?
This filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but does not detail specific new material events or financial results within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Acrivon Therapeutics, Inc. (ACRV).